Neurontin generics “approvable”
Executive Summary
Ivax, Eon and Purepac ANDAs for generic versions of Pfizer's Neurontin (gabapentin) are "approvable" at FDA pending resolution of language in labeling referring prescribers to Pfizer's label for protected pediatric information. After labeling issues are resolved, the ANDAs will be tentatively approved until the 30-month stay of approval related to Pfizer's "lactam-free" bulk gabapentin expires in December (1"The Pink Sheet" Dec. 24, 2001, p. 18)...
You may also be interested in...
Pfizer Pregabalin NDA Will Include Anxiety Use; Filing Date Pushed To 2002
Pfizer's updated pregabalin NDA filing schedule calls for three initial indications - add-on epilepsy, neuropathic pain and generalized anxiety disorder - to be submitted in 2002
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.